Epidemiological Surveillance of SARS-CoV-2 Infections

Epidemiological surveillance of SARS-CoV-2 encompasses the systematic collection, analysis and interpretation of data on viral transmission, clinical presentation and immune responses to guide public-health interventions. Early in the pandemic, case-based surveillance employing laboratory confirmation of viral RNA in respiratory specimens underpinned rapid case detection and contact tracing. As outbreaks evolved, serological surveys provided complementary insights into population exposure, revealing asymptomatic infections and the extent of pre-symptomatic spread. Syndromic surveillance in emergency departments and general practice networks tracked excess influenza-like illness, signalling cryptic community transmission. Integration of genomic sequencing has refined the mapping of introduction events and chains of transmission, informing travel restrictions and local control measures. Together, these approaches have guided decisions on non-pharmaceutical interventions, vaccine deployment and health-system preparedness, highlighting the global significance of real-time data sharing and standardised methodologies for managing emerging infectious threats.

Research from Nature Portfolio

A longitudinal analysis of asymptomatic individuals monitored the development and persistence of antibodies against the spike receptor-binding domain over eight weeks. Despite confirmed infection by PCR or initial serology, around 80% lost detectable immunoglobulins within two months and over 40% never mounted a measurable antibody response. These findings emphasise the limitations of relying solely on seroprevalence to estimate true infection rates and suggest the need for multi-modality surveillance combining molecular testing, serology and clinical reporting to capture the full spectrum of SARS-CoV-2 transmission.

Epidemiological Surveillance of SARS-CoV-2 Infections publication trend

The graph below shows the total number of articles in epidemiological surveillance of sars-cov-2 infections across all publications each year (not limited to Nature Index journals).

Technical terms

Serological surveillance: Monitoring of population-level antibody prevalence to assess past infection and immunity.

Syndromic surveillance: Collection of clinical syndrome data (e.g., influenza-like illness) to detect unusual increases in disease activity.

Genomic sequencing: Determination of viral genetic code to trace transmission pathways and identify introduction events.

Asymptomatic infection: Presence of infection without observable clinical symptoms, contributing to silent transmission.

Neutralising antibody: Immunoglobulin that inhibits viral entry into host cells and serves as a proxy for protective immunity.

References

1. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Eurosurveillance (2020).
2. Excess cases of influenza-like illnesses synchronous with coronavirus disease (COVID-19) epidemic, France, March 2020. Eurosurveillance (2020).
3. Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. Tumori Journal (2020).
4. Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020. Clinical Infectious Diseases (2020).
5. Serological follow-up of SARS-CoV-2 asymptomatic subjects. Scientific Reports (2020).